Through ProAct's Advantage and Core formulary options, we use our unmatched scale and proven track record to advocate on our clients behalf, leveraging negotiations to provide competitive pricing. When clinical considerations align with these opportunities, patients and payers benefit. On January 1, 2026, ProAct will exclude 50 additional products from the Advantage formulary, demonstrating our commitment to minimizing health care waste by excluding high-cost medications that may not provide greater clinical results. These exclusions include the intravenous formulation of Stelara® and the subcutaneous formulation of Stelara® will be excluded for new utilizers. Stelara® will be excluded for all Advantage existing utilizers effective July 1, 2026.
The full list of changes is available by visiting our website: https://secure.proactrx.com/
